Just weeks after its launch, San Diego-based Tragara has announced a $40 million first round of venture financing to support its work in cancer and inflammatory diseases. Domain Associates, ProQuest Investments, Morgenthaler Ventures, Oxford Bioscience Partners, and Mitsubishi International Corporation all participated. Tragara will be led by the management team responsible for the recent sale of Cabrellis Pharmaceuticals to Pharmion Corporation in November 2006. CEO Thomas Estok is joined by Tracy Lawhon, J.D., who will serve as vice president, regulatory affairs and development operations. Christopher C. LeMasters has been chosen as chief business officer, and Sara Zaknoen, M.D., will serve as chief medical officer.
- here's the release on the round